Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 265.855 -3.095 (-1.15%) Market Cap: 34.29 Bil Enterprise Value: 33.21 Bil PE Ratio: 0 PB Ratio: 1,063.42 GF Score: 78/100

Alnylam Pharmaceuticals Inc at Oppenheimer Healthcare Conference (Virtual) Transcript

Mar 15, 2023 / 05:20PM GMT
Release Date Price: $185.75 (-0.72%)
Leland James Gershell
Oppenheimer & Co. Inc., Research Division - MD & Senior Analyst

Thank you, and good afternoon, everyone. Welcome back to another session here at the third day of Oppenheimer's 33rd Annual Healthcare Conference. I'm Leland Gershell, one of the analysts on the biotech equity research team here at Oppenheimer, and we're very delighted to have with us Alnylam Pharmaceuticals, will be having a fireside chat with Akshay Vaishnaw, who's the President of Alnylam.

We do cover Alnylam stock with an outperform rating. And we will have about half an hour to have a good discussion. If you do have any questions, feel free to send those over. I will see if I can work those in. But I think we're pretty good in terms of our road map for this. So Akshay, thank you very much, and welcome to the chat.

Akshay K. Vaishnaw
Alnylam Pharmaceuticals, Inc. - President

Leland, thanks so much for inviting me. And it's my pleasure.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot